false
0001526119
0001526119
2024-01-29
2024-01-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 29, 2024
Verastem,
Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware |
|
001-35403 |
|
27-3269467 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
117 Kendrick Street, Suite 500, Needham, MA |
|
02494 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (781) 292-4200
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
Common stock, $0.0001 par value per share |
|
VSTM |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure
On January 29, 2024, Verastem, Inc. issued a press release
outlining key 2024 strategic priorities and upcoming catalysts, a copy of which is furnished hereto as Exhibit 99.1 to this Current
Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VERASTEM, INC. |
|
|
|
Dated: January 29, 2024 |
By: |
/s/ Daniel W. Paterson |
|
|
Daniel W. Paterson |
|
|
Chief Executive Officer |
Exhibit 99.1
Verastem Oncology Outlines Key 2024 Strategic Priorities
and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
January 29, 2024 at 7:00 AM EST
Expect to Begin Rolling Submission of New Drug Application
(NDA) for Accelerated Approval to FDA for Avutometinib and Defactinib Regimen in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in
H1 2024; Prepare for Potential Commercial Launch in 2025
Initial Data Read-Out from RAMP 205 Trial of Avutometinib
and Defactinib Combination Plus Standard of Care Chemotherapy in Frontline Metastatic Pancreatic Cancer Planned for H1 2024
Data from RAMP 203 and RAMP 204 Trials in KRAS G12C-Mutant Non-Small
Cell Lung Cancer (NSCLC) Planned for Mid-2024
BOSTON--(BUSINESS WIRE)--Jan. 29, 2024-- Verastem Oncology
(Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic
priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.
“We have
made significant progress in our commitment to advancing new solutions for RAS pathway-driven cancers and look forward to an
exciting and catalyst-filled year ahead. With plans to submit an NDA for Accelerated Approval for the combination of avutometinib
and defactinib in recurrent low-grade serous ovarian cancer in the first half of this year, we are working rapidly to bring forward
the first potential therapy approved by the U.S. Food and Drug Administration for patients with LGSOC in need of better treatment
options,” said Dan Paterson, President and Chief Executive Officer of Verastem Oncology. “Further, we plan to provide
data read-outs with avutometinib and defactinib combinations in KRAS G12C-mutant non-small cell lung cancer and frontline metastatic
pancreatic cancer, as well as supporting our collaborator GenFleet in advancing oral KRAS G12D inhibitor GFH375/VS-7375 into a Phase
1 clinical trial this year.”
2023 and Recent Accomplishments
| · | Presented interim results from the Phase 1/2 RAMP 201 trial
of avutometinib and defactinib in LGSOC, including an objective response rate (ORR) of 45% (13/29) and disease control in 86% (25/29)
of evaluable patients. Safety and tolerability continued to be favorable and consistent with previously reported data. |
| · | Finalized design with the FDA and initiated confirmatory Phase
3 RAMP 301 trial to evaluate the efficacy and safety of avutometinib and defactinib versus standard chemotherapy or hormonal therapy
for the treatment of recurrent LGSOC. |
| · | Launched patient and healthcare professional initiatives, including
Let’s Talk About LGSOC , designed to support clinicians in the diagnosis and management of LGSOC and to provide information,
resources and support to patients. Engaged with more than 25% of the recurrent LGSOC patient population. |
| · | Presented initial results from Phase 1/2 RAMP 203 trial evaluating
the efficacy and safety of avutometinib and sotorasib in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) who have or
have not been previously treated with a KRAS G12C inhibitor. The confirmed ORR was 25% (3/12) across efficacy-evaluable patients and
responses observed in both KRAS G12C inhibitor resistant (14.3%; 1/7) and naïve (40%; 2/5) patients. Avutometinib 4.0 mg by mouth
biweekly (BIW) 21/28 days and sotorasib 960 mg by mouth once-daily (QD) 28/28 days was selected as the recommended Phase 2 dose based
on dose limiting toxicity assessment. |
| · | Received Fast Track designation from the FDA for avutometinib,
in combination with Amgen’s G12C inhibitor, LUMAKRAS™ (sotorasib), for the treatment of patients with KRAS G12C-mutant metastatic
NSCLC who have received at least one prior systemic therapy and have not been previously treated with a KRAS G12C inhibitor. |
| · | Entered into a discovery and development collaboration with
GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers. Completed
investigational new drug (IND)-enabling GLP toxicology studies for oral KRAS G12D inhibitor GFH375/VS-7375, selected as lead program. |
Strategic Priorities and Anticipated 2024 Milestones and Catalysts
LGSOC Program
| · | Begin submission of an NDA to the FDA for Accelerated Approval
for the combination of avutometinib and defactinib in recurrent LGSOC in H1 2024; prepare for potential commercial launch in 2025. |
| · | Present full data from Part A and Part B of RAMP 201 trial in
LGSOC at a scientific medical conference in H1 2024. |
| · | Initiate discussions with European and Japanese regulatory authorities
for the avutometinib and defactinib regimen in LGSOC to address patient needs outside the U.S. |
KRAS G12C-Mutant NSCLC Program
| · | Based on stronger tumor regressions in KRAS G12C-mutant NSCLC
preclinical models when FAKi is added along with G12Ci + avutometinib, add defactinib to the RAMP 203 trial
of avutometinib with sotorasib. |
| · | Data updates from RAMP 203 and RAMP 204 trials planned for mid-2024. |
Frontline Metastatic Pancreatic Cancer Program
| · | Present initial safety and efficacy results from RAMP 205 trial
of avutometinib and defactinib in combination with standard of care gemcitabine and nab-paclitaxel in frontline metastatic pancreatic
cancer in H1 2024. |
GenFleet Collaboration
| · | GenFleet expected to submit an IND for GFH375/VS-7375 in China
for patient with KRAS G12D mutations in H1 2024 and begin a Phase 1 trial for GFH375/VS-7375 in China in H2 2024. |
| · | Companies to continue discovery/lead optimization for second
and third programs. |
About the Avutometinib and Defactinib Combination
Avutometinib is a RAF/MEK clamp that induces inactive complexes
of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
In contrast to currently available MEK inhibitors, avutometinib blocks both MEK kinase activity and the ability of RAF to phosphorylate
MEK. This unique mechanism allows avutometinib to block MEK signaling without the compensatory activation of MEK that appears to limit
the efficacy of other inhibitors. The U.S. Food and Drug Administration granted Breakthrough Therapy designation for the combination
of Verastem Oncology’s investigational RAF/MEK clamp avutometinib, with defactinib, its FAK inhibitor, for the treatment of all
patients with recurrent LGSOC regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy.
Verastem Oncology is currently conducting clinical trials
with its RAF/MEK clamp avutometinib in RAS pathway-driven tumors as part of its (Raf And Mek Program). RAMP
301 is a Phase 3 confirmatory trial evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal
therapy for the treatment of recurrent LGSOC. RAMP 201 is a Phase 2 registration-directed trial of avutometinib in combination with defactinib
in patients with recurrent LGSOC and has completed enrollment in the dose optimization and expansion phases and is enrolling for low-dose
evaluation. Verastem Oncology has established clinical collaborations with Amgen and Mirati to evaluate LUMAKRAS™ (sotorasib) and
KRAZATI™ (adagrasib) in combination with avutometinib in KRAS G12C mutant NSCLC as part of the RAMP 203 and RAMP 204 trials, respectively.
Supported by the “Therapeutic Accelerator Award” Verastem Oncology received from PanCAN, the Company is conducting RAMP 205,
a Phase 1b/2 clinical trial evaluating avutometinib and defactinib with gemcitabine/nab-paclitaxel in patients with front-line metastatic
pancreatic cancer.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage
biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed
with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer
cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please
visit www.verastem.com.
Forward-Looking Statements Notice
This press release includes forward-looking
statements about Verastem Oncology’s strategy, future plans and prospects, including statements related to the expected outcome
and benefits of the collaboration with GenFleet, the potential clinical value of various of its clinical trials, the timing of commencing
and completing trials, including topline data reports, interactions with regulators, the potential for and timing of commercialization
of product candidates and potential for additional development programs involving Verastem Oncology’s lead compound. The words
"anticipate," "believe," "estimate," "expect," "intend," "may," "plan,"
"predict," "project," "target," "potential," "will," "would," "could,"
"should," "continue," “can,” “promising” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement
is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks and
uncertainties, among other things, regarding: the success in the development and potential commercialization of our product
candidates, including avutometinib in combination with other compounds, including defactinib, LUMAKRAS™ and others; the
uncertainties inherent in research and development, such as negative or unexpected results of clinical trials, the occurrence or
timing of applications for our product candidates that may be filed with regulatory authorities in any jurisdictions; whether and
when regulatory authorities in any jurisdictions may approve any such applications that may be filed for our product candidates,
and, if approved, whether our product candidates will be commercially successful in such jurisdictions; our ability to obtain,
maintain and enforce patent and other intellectual property protection for our product candidates; the scope, timing, and outcome of
any legal proceedings; decisions by regulatory authorities regarding trial design, labeling and other matters that could affect the
timing, availability or commercial potential of our product candidates; whether preclinical testing of our product candidates and
preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials;
that the timing, scope and rate of reimbursement for our product candidates is uncertain; that third-party payors (including
government agencies) may not reimburse; that there may be competitive developments affecting our product candidates; that data may
not be available when expected; that enrollment of clinical trials may take longer than expected; that our product candidates will
cause adverse safety events and/or unexpected concerns may arise from additional data or analysis, or result in unmanageable safety
profiles as compared to their levels of efficacy; that our product candidates may experience manufacturing or supply interruptions
or failures; that any of our third party contract research organizations, contract manufacturing organizations, clinical sites, or
contractors, among others, who we rely on fail to fully perform; that we face substantial competition, which may result in others
developing or commercializing products before or more successfully than we do which could result in reduced market share or market
potential for our product candidates; that we will be unable to successfully initiate or complete the clinical development and
eventual commercialization of our product candidates; that the development and commercialization of our product candidates will take
longer or cost more than planned, including as a result of conducting additional studies; that we may not have sufficient cash to
fund our contemplated operations; that we may not attract and retain high quality personnel; that we or Chugai Pharmaceutical Co.,
Ltd. will fail to fully perform under the avutometinib license agreement; that our target market for our product candidates might be
smaller than we are presently estimating; that Secura Bio, Inc. will fail to fully perform under the asset purchase agreement with
Secura Bio, Inc., including in relation to milestone payments; that we will not see a return on investment on the payments we have
and may continue to make pursuant to the collaboration and option agreement with GenFleet or that GenFleet will fail to fully
perform under the agreement; that we may be unable to obtain adequate financing in the future through product licensing,
co-promotional arrangements, public or private equity, debt financing or otherwise; that we will not pursue or submit regulatory
filings for our product candidates; and that our product candidates will not receive regulatory approval, become commercially
successful products, or result in new treatment options being offered to patients.
Other risks and uncertainties include those identified under
the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed
with the Securities and Exchange Commission (SEC) on March 14, 2023 and in any subsequent filings with the SEC. The forward-looking statements
contained in this press release reflect Verastem Oncology’s views as of the date hereof, and the Company does not assume and specifically
disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise,
except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124822477/en/
Investors:
Ryan Porter
Argot Partners
+1 212-600-1902
ryan.porter@argotpartners.com
Media:
Verastem Oncology
media@verastem.com
Source: Verastem Oncology
v3.24.0.1
Cover
|
Jan. 29, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 29, 2024
|
Entity File Number |
001-35403
|
Entity Registrant Name |
Verastem,
Inc.
|
Entity Central Index Key |
0001526119
|
Entity Tax Identification Number |
27-3269467
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
117 Kendrick Street
|
Entity Address, Address Line Two |
Suite 500
|
Entity Address, City or Town |
Needham
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02494
|
City Area Code |
781
|
Local Phone Number |
292-4200
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common stock, $0.0001 par value per share
|
Trading Symbol |
VSTM
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Jul 2023 to Jul 2024